Business Wire

BIOLOG-ID

23.11.2021 15:18:11 CET | Business Wire | Press release

Share
Troy Hilsenroth Appointed CEO of biolog-id

As part of the biolog-id international deployment and in its preparation for going public, the company’s board of directors have designated Troy Hilsenroth as CEO of biolog-id worldwide. This appointment is effective since November 1st , 2021.

Fortified by 29 years of experience, Troy Hilsenroth has in-depth healthcare expertise. Before joining biolog­id as CEO of biolog-id LLC North-America in 2019, he was previously vice president and general manager of the medication adherence division at Omnicell, where he built and grew a global division over the last 10 years. Prior to this, he led management and staff pharmacy positions at renowned healthcare organizations.

“After 2 years as CEO for the North American region, I’m very proud and excited to take the lead of all biolog-id activities”, declare Troy Hilsenroth. “From the very beginning, I’m convinced that biolog-id has a significant potential to contribute to the digital transformation of the healthcare industry and I am very honored to take on this new position to support the company in its preparation for going public. I’m looking forward to – together with the Board and all collaborators – writing the next chapter of this success story”.

“As founder and Chairman of the Board of the company, I’m delighted to have Troy Hilsenroth taking these new responsibilities”, announces Jean-Claude Mongrenier. “The previous years spent in the company proven that Troy has a leading vision on how to develop our business, he has successfully deployed our solutions at major US Blood Banking institutions. We all agreed that Troy Hilsenroth is a standout leader, and the Board is confident that he will create the necessary conditions for entering in the stock market”.

Founded in 2005, biolog-id has patented technology that allows healthcare professionals to track, trace and manage sensitive healthcare products throughout their journey, from donor to patient. With more than 100 employees, the company currently operates in 14 countries throughout North America, Europe, the Middle East, India and the Asia-Pacific region.

About biolog-id :
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and Xerys Invest. Xerys Invest is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies.
Company URL: www.biolog-id.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer8.10.2026 13:30:00 CEST | Press release

Botvymo® (botensilimab) and Evamplix® (balstilimab) receive separate approvals for use in combinationArmenia is the first country to approve marketing authorization of BOT+BAL, following a rigorous review of quality, nonclinical, clinical and pharmacovigilance dataApprovals supported by clinical evidence published in peer-reviewed journals and presented at major oncology congresses, including two-year Phase 1b survival findings and randomized Phase 2 data in MSS metastatic colorectal cancer without active liver metastasesAgenus will evaluate the potential for approvals in other Eurasian Economic Union countries that support this regulatory path Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo® (botensilimab, BOT) and Evamplix® (balstilimab, BAL), each approved for use in combination with the other for the treatment of adult patients with microsatell

NTT DOCOMO BUSINESS and Classiq Enter Strategic Business Partnership to Accelerate Enterprise Adoption of Quantum Computing8.10.2026 13:00:00 CEST | Press release

Combining Classiq’s quantum software development platform with NTT DOCOMO BUSINESS's real-world implementation expertise to accelerate enterprise quantum adoption NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) and Classiq Technologies G.K., the Japanese subsidiary of Classiq Technologies Ltd., today announced a memorandum of understanding establishing a strategic business partnership aimed at accelerating enterprise adoption of quantum computing1 in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007985427/en/ NTT DOCOMO BUSINESS and Classiq logos Under the partnership, NTT DOCOMO BUSINESS will propose and sell the Classiq quantum software development platform and work with Classiq to help enterprises identify, develop and validate quantum computing use cases. Classiq will provide the platform, along with expertise and technical support related to quantum algorithms and quantum software technolo

Movado Group, Inc. Enters Into Agreement to Sell Majority Interest in EBEL8.10.2026 12:45:00 CEST | Press release

Movado Group, Inc. (NYSE: MOV) today announced that it has entered into a binding agreement to sell a 95% interest in its EBEL brand for $66.5 million to a strategic buyer group led by Montres Journe SA (“Montres Journe”), a Geneva-based luxury watch manufacturer, with the participation of Chanel (“Chanel”), the luxury house, and Pierre Jacques, a renowned figure in the Swiss watch industry, who will serve as Chief Executive Officer of EBEL. The transaction is subject to customary adjustments and closing conditions with Movado Group retaining a 5% interest in the business. Founded in Switzerland in 1911, EBEL is a premium luxury watch brand known for its distinctive design, craftsmanship and rich heritage. This strategic sale allows Movado Group to sharpen its focus on its core accessible luxury and fashion watch and jewelry portfolio, while providing EBEL with a new ownership platform specifically positioned to support the brand’s long-term development. With the expertise and capital

NIQ Reaches Key Milestone in Acquisition of The U Group, Strengthening Trusted Intelligence and The Full View™8.10.2026 12:45:00 CEST | Press release

NielsenIQ (NYSE: NIQ) today announced that its wholly-owned Australian subsidiary, Nielsen Connect Australia Pty Ltd (NIQ Australia), has exceeded the 90% shareholder acceptance threshold under its off-market takeover bid for The U Group & Co Limited (The U Group), an Australian-based company specializing in consumer participation, receipt intelligence, and AI-powered data processing capabilities. Achieving the acceptance threshold represents a significant milestone in the transaction process and enables NIQ Australia to proceed with the compulsory acquisition of the remaining shares in The U Group in accordance with applicable Australian law. Building on a successful five-year partnership, the transaction strengthens NIQ's trusted intelligence foundation and advances its strategy to deliver the industry's most complete understanding of consumer buying behavior. By bringing together NIQ's measurement, analytics, and consumer intelligence capabilities with The U Group's consumer partici

Network X 2026 Brings Europe’s Telecom Leaders Together in Vienna to Define the Future of Connectivity8.10.2026 12:42:00 CEST | Press release

A1 Group, Swisscom, Orange, Deutsche Telekom, Vodafone, Drei Austria, 4iG, Kyivstar and other industry leaders headline telecoms premier event Network X 2026 unites the telecommunications industry’s most influential executives and technology leaders at VIECON Vienna from 13-15 October, with a high-powered Headliners programme focused on the forces reshaping the future of connectivity. Across three days, CEOs, CTOs, technology chiefs, regulators and industry experts from leading operators and technology organisations will examine how artificial intelligence, network sovereignty, broadband networks, 6G, cloud, infrastructure investment and new business models are changing the role of the telecom operator. The programme features senior executives from A1 Group, Swisscom, Drei Austria, A1 Austria, Orange, Deutsche Telekom, Vodafone Group, Kyivstar, 4iG Telecommunications Holding, Yettel Bulgaria, Play Poland, Orange Slovensko, NGMN Alliance and other major players across the global connect

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye